However, a stage III trial comparing nivolumab (anti-PD-1 monoclonal antibody) and bevacizumab (anti-VEGF monoclonal antibody) in 369 patients with recurrent GBM did not prove the benefit of nivolumab [34]. This evidence concerns the gene PDCD1 and glioblastoma.